Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV003236379 | SCV003934328 | likely pathogenic | Familial hyperinsulinism | 2023-05-03 | criteria provided, single submitter | clinical testing | Variant summary: GCK c.1354G>C (p.Val452Leu) results in a conservative amino acid change located in the Hexokinase, C-terminal domain (IPR022673) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 240586 control chromosomes. c.1354G>C has been reported in the literature as a de-novo variant in at-least one individual affected with Congenital Hyperinsulinism (example, Meissner_2009 cited in Sayed_2009, Ping_2019 and Gilis-Januszewska_2021) and as a rare cause of recurrent hypoglycemia in a 21 year old treated for persistent hyperinsulinemic hypoglycemia of infancy (example, Ajala_2016). These data indicate that the variant may be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function (Zelent_2011). The most pronounced variant effect results in characterization as an activating mutation consistent with the mechanism of disease. The following publications have been ascertained in the context of this evaluation (PMID: 27802864, 34680961, 34532767, 19053014, 31094068, 25733449, 19336674, 23890519, 21831042). No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic. |